title: Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD).
abstract: Meibomian gland (MG) dysfunction (MGD) is a multifactorial, chronic condition of the eyelids, leading to eye irritation, inflammation and ocular surface disease. Initial conservative therapy often includes a combination of warm compresses in addition to baby shampoo or eyelid wipes. The practice of lid hygiene dates back to the 1950s, when selenium sulfide-based shampoo was first used to treat seborrhoeic dermatitis of the eyelids. Today, tear-free baby shampoo has replaced dandruff shampoo for MGD treatment and offers symptom relief in selected patients. However, many will not achieve significant improvement on this therapy alone; some may even develop an allergy to the added dyes and fragrances in these products. Other manual and mechanical techniques to treat MGD include MG expression and massage, MG probing and LipiFlow(®). While potentially effective in patients with moderate MGD, these procedures are more invasive and may be cost prohibitive. Pharmacological treatments are another course of action. Supplements rich in omega-3 fatty acids have been shown to improve both MGD and dry eye symptoms. Tea tree oil, specifically the terpenin-4-ol component, is especially effective in treating MGD associated with Demodex mites. Topical antibiotics, such as azithromycin, or systemic antibiotics, such as doxycycline or azithromycin, can improve MGD symptoms both by altering the ocular flora and through anti-inflammatory mechanisms. Addressing and treating concurrent ocular allergy is integral to symptom management. Topical N-acetylcysteine and topical cyclosporine can both be effective therapeutic adjuncts in patients with concurrent dry eye. A short course of topical steroid may be used in some severe cases, with monitoring for steroid-induced glaucoma and cataracts. While the standard method to treat MGD is simply warm compresses and baby shampoo, a more tailored approach to address the multiple aetiologies of the disease is suggested.
authors.affiliation: New York Eye and Ear Infirmary of Mount Sinai, 150 East 32nd Street #102, New York, NY, USA.
authors.forename: Adam R
authors.initials: AR
authors.lastname: Thode
authors.forename: Robert A
authors.initials: RA
authors.lastname: Latkany
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015195:Drug Design; D005141:Eyelid Diseases / Q000188:drug therapy* / Q000503:physiopathology; D006203:Hair Preparations / Q000737:chemistry; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D008537:Meibomian Glands / Q000503:physiopathology*
chemical_list: D000893:Anti-Inflammatory Agents; D006203:Hair Preparations